HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $105 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a price target of $105.
August 09, 2023 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $105.
The reiterated 'Buy' rating and maintained price target of $105 by HC Wainwright & Co. indicates a positive outlook for Denali Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100